Leyden Laboratories B.V. has announced new clinical and preclinical findings demonstrating that its intranasal antibody-based spray CR9114 can safely deliver protective antibody levels to the respiratory mucosa, the key entry point for airborne viruses. Published in Science Translational Medicine, the data showed that the candidate, under development as part of the PanFlu program, achieved sustained presence in human nasal cavities and protected non-human primates from influenza infection.

Why mucosal delivery of antibodies could mark a paradigm shift in respiratory virus prevention

Leyden Laboratories’ approach targets what virologists have long considered a critical gap in respiratory virus defense: the initial point of viral entry in the upper airway. Unlike vaccines or monoclonal antibodies administered systemically—which must generate or circulate neutralizing responses throughout the body—PanFlu delivers CR9114 antibodies directly to the nasal mucosa. This method aims to stop the virus before it infects cells, mimicking how naturally occurring mucosal immunity works but without requiring an individual’s immune system to mount a response.

For clinicians and researchers focused on prevention strategies during emergent flu strains or variant shifts, this method could prove especially timely. The intranasal approach bypasses the need for full systemic immunity and is potentially suitable for immunocompromised individuals, a group often underprotected by traditional vaccines.

What stands out in Leyden’s data is the ability of CR9114—a broadly neutralizing antibody previously licensed from Janssen Pharmaceuticals, Inc.—to retain antiviral functionality even after prolonged residence in the nasal cavity. Combined with favorable safety data across 143 healthy volunteers in Phase 1 trials, the results hint at a novel product class: prophylactic, off-the-shelf antibody sprays capable of delivering immediate protection during flu seasons or outbreaks.

How this strategy compares to the current standard of flu vaccines and antivirals

While influenza vaccines have evolved, they remain largely strain-specific and depend on prediction models months in advance of flu season. This temporal gap often results in mismatches between circulating strains and vaccine components. Additionally, traditional vaccination requires time to stimulate adaptive immunity—posing challenges during rapid outbreaks or among patients with compromised immune responses.

By contrast, CR9114’s mechanism centers on passive immunization. It does not require the host to generate antibodies, offering potential for immediate action. The non-human primate study further strengthened this argument: animals given intranasal CR9114 demonstrated significant reductions in viral replication and viral load after H1N1 exposure.

Industry analysts point out, however, that while this approach excels in immediacy, questions remain around the duration of protection. Seasonal flu vaccines, despite their imperfections, can provide months of immunity. Whether intranasal antibodies can match or complement this coverage is still unknown.

From a public health perspective, intranasal antibody sprays might not replace flu vaccines but could serve as critical adjuncts—especially during vaccine production delays, pandemic outbreaks, or in vulnerable populations who cannot mount robust immune responses.

What regulators, manufacturers, and clinicians will scrutinize next

Bringing a nasal spray-based biologic like CR9114 to market introduces complexity beyond standard drug development. First, intranasal delivery of monoclonal antibodies is a novel regulatory category with limited precedent. Regulatory watchers suggest that agencies such as the U.S. Food and Drug Administration and the European Medicines Agency will likely focus on pharmacokinetics at the mucosal surface, reproducibility of delivery, and real-world consistency in antibody retention.

Second, ensuring scalable manufacturing of a protein-based nasal formulation is no small feat. The product must retain stability through cold-chain transport, exhibit consistent mucosal bioavailability across diverse populations, and avoid degradation due to environmental exposure. These logistics differ significantly from systemic antibody therapies, which are typically administered in controlled clinical settings.

Moreover, clinicians tracking the field will be alert to any adverse events linked to repeated use, particularly local inflammation or desensitization of nasal mucosa. Ensuring patient adherence—especially for pre-exposure prophylactic use—will also be a challenge unless product administration becomes as effortless and routine as using over-the-counter nasal sprays.

What makes CR9114 a unique candidate—and what gaps remain in understanding

CR9114 is widely recognized in influenza research circles as one of the most broadly neutralizing monoclonal antibodies targeting conserved regions of the influenza virus. Its inclusion in Leyden Laboratories’ PanFlu spray elevates the credibility of the program. Yet while this scientific foundation is strong, clinical utility will depend on how long the antibody remains functional in the nasal cavity, how often it needs to be reapplied, and whether this remains effective against newer or highly divergent flu strains.

There is also an open question about pricing and positioning. Monoclonal antibodies, even at low dosages, remain expensive to manufacture. If PanFlu is intended for broad seasonal use across populations, cost-effectiveness will need to be proven—not just in terms of product pricing, but through health-economic models showing reduced hospitalizations, transmission rates, or outbreak containment.

Furthermore, adoption will depend on whether national immunization programs, payers, or pandemic preparedness frameworks see value in stockpiling or subsidizing such intranasal prophylactics. In resource-constrained regions, spray-based delivery could appear more attractive than injectable alternatives—but only if price and access hurdles are addressed early.

Could this pave the way for a new product category in pandemic preparedness?

Observers of pandemic preparedness frameworks note that intranasal antibody sprays could become an essential part of the next-generation arsenal against airborne pathogens. Their ease of deployment, potential for at-home use, and immediacy of action position them well as first-line defenses during the early stages of an outbreak—especially for novel influenza strains or coronaviruses with high transmission potential.

However, the need for rapid, sustained antibody coverage raises concerns around dosing frequency and formulation shelf-life. If repeat administration is required every few days or weekly, adherence and logistics could quickly become bottlenecks. Moreover, broad regulatory acceptance will depend on demonstrating not just proof-of-concept, but a clear clinical benefit over placebo or existing prophylactic strategies.

If these hurdles are overcome, Leyden Laboratories may have cracked open a new category of mucosal biologics—products designed not to treat disease after infection but to intercept pathogens before they breach the body’s first immune barrier.

  biologics, CR9114, flu vaccine alternatives, influenza prevention, intranasal antibody spray, Leyden Laboratories, mucosal immunity, PanFlu, respiratory viruses